title: Acute tubulointerstitial nephritis following intravenous immunoglobulin therapy in a male infant with minimal-change nephrotic syndrome.
abstract: A boy aged 4 years with nephrotic syndrome (NS) was referred to our hospital because of the third relapse of NS. Hypogammaglobulinemia associated with massive proteinuria was observed at the presentation. Residual urinary tract infection required intravenous piperacillin and immunoglobulin therapy (IVIG). Soon after IVIG, he complained of high fever with chills, bilateral knee joint pain, dry cough and chest discomfort. Although he did not develop renal insufficiency, a transient increase in the urinary beta2-microglobulin and decrease in the serum complement hemolytic activity were observed. These clinical manifestations spontaneously ceased. A percutaneous renal biopsy for his NS performed 19 days after the episode of allergic reaction revealed tubulointerstitial nephritis (TIN) with marked eosinophil infiltrates. Glomeruli showed minor glomerular abnormalities. Renal complications associated with IVIG treatment have been reported to date, however, acute TIN has rarely been seen.
authors.affiliation: Department of Pediatrics, Hirosaki University School of Medicine, Japan. hirotana@cc.hirosaki-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Waga
authors.forename: T
authors.initials: T
authors.lastname: Tateyama
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kakizaki
authors.forename: M
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D000208:Acute Disease; D000361:Agammaglobulinemia / Q000209:etiology / Q000628:therapy; D015415:Biomarkers; D001706:Biopsy; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects*; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007668:Kidney / Q000473:pathology; D008297:Male; D009395:Nephritis, Interstitial / Q000209:etiology* / Q000473:pathology; D009404:Nephrotic Syndrome / Q000150:complications* / Q000628:therapy; D010406:Penicillins / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D012008:Recurrence; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D001613:beta 2-Microglobulin / Q000652:urine
chemical_list: D015415:Biomarkers; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010406:Penicillins; D001613:beta 2-Microglobulin; D011239:Prednisolone; D010878:Piperacillin